5414x -

: A refined commercial strategy identified high-priority opportunities in applied and research markets worth an estimated $13 to $14 billion .

: Continued advancement in national programs like NIHR Bioresource. Strategic and Operational Developments

The full regulatory document can be accessed through the London Stock Exchange or financial news platforms like ADVFN . Interim results for the 6 months ended 30 June 25

: Completed a programme resulting in an approximately 5% reduction in workforce to reallocate capital to growth areas.

: Introduced next-generation automated flow cell lines and strengthened quality assurance to ISO 13485 standards.